Clinical Trials
Details
Gradalis Immunotherapy Platform
High Risk Stage III/IV Ovarian Cancer
Phase III
High Risk Stage III/IV Ovarian Cancer
Closed

Randomized Phase 2/3 Trial of Maintenance Vigil® for High Risk Stage III/IV Ovarian Cancer

Ewing's Sarcoma
Phase II
Ewing's Sarcoma
Closed

Randomized Phase 2b Trial of Vigil® EATC immunotherapy versus gemcitabine + docetaxel for Ewing's Sarcoma

Advanced Breast Cancer
Phase II
Advanced Breast Cancer
Recruiting

Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil® in Advanced Breast Cancer

Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Closed

Open Label Phase 2 Study of Vigil® + Nivolumab in Advanced Non-Small Cell Lung Cancer

Advanced Melanoma
Advanced Melanoma
Closed

Pilot Study of Vigil® + Pembrolizumab for Advanced Melanoma

Gradalis® Clinical Trials